Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.
The fact that adenoviral vectors activate innate immunity and induce type I IFNs has not been fully appreciated in the context of cancer gene therapy. Type I IFNs influence different aspects of human immune response and are believed to be crucial for efficient tumor rejection. We performed transcriptional profiling to characterize the response of cutaneous lymphomas to intralesional adenovirus-mediated IFN-gamma (Ad-IFN-gamma) gene transfer. Gene expression profiles of skin lesions obtained from 19 cutaneous lymphoma patients before and after treatment with Ad-IFN-gamma revealed a distinct gene signature consisting of IFN-gamma- and numerous IFN-alpha-inducible genes (type II- and type I-inducible genes, respectively). The type I IFN response appears to have been induced by the vector itself, and its complexity, in terms of immune activation, was potentiated by the IFN-gamma gene insert. Intralesional IFN-gamma expression together with the induction of a combined type I/II IFN response to Ad-IFN-gamma gene transfer seem to underlie the objective (measurable) clinical response of the treated lesions. Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads.
Urosevic
Mirjana
M
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. mirjana.urosevic@usz.ch
Fujii
Kazuyasu
K
Calmels
Bastien
B
Laine
Elisabeth
E
Kobert
Nikita
N
Acres
Bruce
B
Dummer
Reinhard
R
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D002478:Cells, Cultured; D020869:Gene Expression Profiling; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D007370:Interferon Type I / Q000276:immunology*; D007371:Interferon-gamma / Q000235:genetics*; D008223:Lymphoma / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D012878:Skin Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy